Section of Social Medicine, Department of Public Health, University of Copenhagen, Copenhagen K, Denmark.
Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen Ø, Denmark.
Hum Reprod. 2021 Nov 18;36(12):3152-3160. doi: 10.1093/humrep/deab219.
STUDY QUESTION: Is there an increased risk of breast cancer among women after ART treatment including ovarian hormone stimulation? SUMMARY ANSWER: The risk of breast cancer was slightly increased among women after ART treatment compared to age-matched, untreated women in the background population, and the risk was further increased among women initiating ART treatment when aged 40+ years. WHAT IS KNOWN ALREADY: The majority of breast cancer cases are sensitive to oestrogen, and ovarian hormone stimulation has been suggested to increase the risk of breast cancer by influencing endogenous oestrogen levels. Previous studies on ART treatment and breast cancer have varied in their findings, but several studies have small sample sizes or lack follow-up time and/or confounder adjustment. Recent childbirth, nulliparity and higher socio-economic status are breast cancer risk factors and the latter two are also associated with initiating ART treatment. STUDY DESIGN, SIZE, DURATION: The Danish National ART-Couple II (DANAC II) cohort includes women treated with ART at public and private fertility clinics in 1994-2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with no cancer prior to ART treatment were included (n = 61 579). Women from the background population with similar age and no prior history of ART treatment were randomly selected as comparisons (n = 579 760). The baseline mean age was 33.1 years (range 18-46 years). Results are presented as hazard ratios (HRs) with corresponding CIs. MAIN RESULTS AND THE ROLE OF CHANCE: During follow-up (median 9.69 years among ART-treated and 9.28 years among untreated), 5861 women were diagnosed with breast cancer, 695 among ART-treated and 5166 among untreated women (1.1% versus 0.9%, P < 0.0001). Using Cox regression analyses adjusted for nulliparity, educational level, partnership status, year, maternal breast cancer and age, the risk of breast cancer was slightly increased among women treated with ART (HR 1.14, 95% CI 1.12-1.16). All causes of infertility were slightly associated with breast cancer risk after ART treatment. The risk of breast cancer increased with higher age at ART treatment initiation and was highest among women initiating treatment at age 40+ years (HR 1.37, 95% CI 1.29-1.45). When comparing women with a first birth at age 40+ years with or without ART treatment, the increased risk among women treated with ART persisted (HR 1.51, 95% CI 1.09-2.08). LIMITATIONS, REASONS FOR CAUTION: Although this study is based on a large, national cohort of women, more research with sufficient power and confounder adjustment is needed, particularly in cohorts with a broad age representation. WIDER IMPLICATIONS OF THE FINDINGS: An increased risk of breast cancer associated with a higher age at ART treatment initiation has been shown. Ovarian stimulation may increase the risk of breast cancer among women initiating ART treatment when aged 40+ years. Age-related vulnerability to hormone exposure or higher hormone doses during ART treatment may explain the increased risk. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by a PhD grant to D.V. from the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Funding for establishing the DANAC II cohort was received from the Ebba Rosa Hansen Foundation. The authors report no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
研究问题:接受包括卵巢激素刺激在内的辅助生殖技术(ART)治疗的女性是否会增加乳腺癌风险?
总结答案:与背景人群中年龄匹配、未经治疗的女性相比,接受 ART 治疗的女性乳腺癌风险略有增加,而在 40 岁以上开始接受 ART 治疗的女性中,这种风险进一步增加。
已知情况:大多数乳腺癌病例对雌激素敏感,卵巢激素刺激被认为通过影响内源性雌激素水平增加乳腺癌风险。以前关于 ART 治疗和乳腺癌的研究结果存在差异,但一些研究样本量较小,或缺乏随访时间和/或混杂因素调整。最近的分娩、未婚和较高的社会经济地位是乳腺癌的风险因素,后两者也与开始 ART 治疗有关。
研究设计、大小和持续时间:丹麦全国辅助生殖技术夫妇 II 期(DANAC II)队列包括 1994 年至 2016 年在公立和私立生育诊所接受 ART 治疗的女性。
参与者/材料、设置和方法:纳入了 ART 治疗前无癌症的女性(n=61579)。从背景人群中选择年龄相似且无 ART 治疗史的女性作为对照(n=579760)。基线平均年龄为 33.1 岁(范围 18-46 岁)。结果以风险比(HR)及其相应的置信区间呈现。
主要结果和机会作用:在随访期间(ART 治疗组中位数为 9.69 年,未治疗组中位数为 9.28 年),5861 名女性被诊断患有乳腺癌,ART 治疗组 695 例,未治疗组 5166 例(1.1%比 0.9%,P<0.0001)。使用 Cox 回归分析调整了不孕的原因、教育水平、婚姻状况、年份、母亲乳腺癌和年龄后,ART 治疗的女性乳腺癌风险略有增加(HR 1.14,95%CI 1.12-1.16)。所有原因的不孕与 ART 治疗后乳腺癌风险略有相关。乳腺癌风险随着 ART 治疗起始年龄的增加而增加,在 40 岁以上开始治疗的女性中风险最高(HR 1.37,95%CI 1.29-1.45)。当比较 40 岁以上首次分娩的女性是否接受 ART 治疗时,ART 治疗组的风险仍然存在(HR 1.51,95%CI 1.09-2.08)。
局限性、谨慎的原因:尽管这项研究基于一个大型的全国性女性队列,但需要更多具有足够效力和混杂因素调整的研究,特别是在具有广泛年龄代表性的队列中。
研究结果的更广泛意义:已经证明,ART 治疗起始年龄较大与乳腺癌风险增加相关。卵巢刺激可能会增加 40 岁以上开始 ART 治疗的女性患乳腺癌的风险。与年龄相关的对激素暴露的脆弱性或 ART 治疗期间更高的激素剂量可能解释了这种风险增加。
研究资金/利益冲突:这项工作得到了丹麦哥本哈根大学健康与医学科学学院博士学位授予给 D.V.的资助。DANAC II 队列的建立得到了 Ebba Rosa Hansen 基金会的资助。作者报告没有利益冲突。
临床试验注册号:无。
Int J Surg Protoc. 2024-10-24
Int J Biol Sci. 2025-3-24
J Reprod Infertil. 2023